Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Labetalol vs remifentanil vs dexmedetomidine for bleeding control during craniotomy
IRCT20141209020258N167Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Oct 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in craniotomy comparing Remifentanil, Dexmedetomidine and Labetalol (3 arms). Primary endpoints: Surgeon satisfaction, Bleeding and 1 more. Started Oct 2021; status: completed.
02
Drugs
labetalolremifentanildexmedetomidine
03
Conditions
craniotomy
Beyond the preview
Go deeper on IRCT20141209020258N167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141209020258N167.